Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease… Read more
Unicycive Therapeutics Inc (UNCY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.159x
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has a cash flow conversion efficiency ratio of -0.159x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.96 Million) by net assets ($37.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Unicycive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Unicycive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Unicycive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unicycive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CTT Systems AB
ST:CTT
|
-0.019x |
|
Kuo Yang Construction Co Ltd
TW:2505
|
0.035x |
|
China Evergrande Group
F:EV1
|
-0.004x |
|
Vizsla Royalties Corp.
V:VROY
|
N/A |
|
GZ4
F:GZ4
|
0.081x |
|
Qinghai Spring Medicinal Resources Technology Co Ltd
SHG:600381
|
-0.008x |
|
Forest Packaging Group Co Ltd
SHG:605500
|
0.009x |
|
MK Electron Co. Ltd
KQ:033160
|
-0.039x |
Annual Cash Flow Conversion Efficiency for Unicycive Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Unicycive Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.43 Million | $-28.57 Million | -3.845x | -180.11% |
| 2023-12-31 | $-3.81 Million | $-18.28 Million | 4.800x | -85.71% |
| 2022-12-31 | $-466.00K | $-15.65 Million | 33.586x | +9699.95% |
| 2021-12-31 | $16.48 Million | $-5.77 Million | -0.350x | -164.05% |
| 2020-12-31 | $-2.67 Million | $-1.46 Million | 0.546x | -58.94% |
| 2019-12-31 | $-884.00K | $-1.18 Million | 1.330x | +107.01% |
| 2018-12-31 | $-1.21 Million | $-775.00K | 0.643x | -- |